Chronic hepatitis C cases set to edge higher across major markets through 2035, says GlobalData

10 July 2026

The number of diagnosed chronic hepatitis C cases is expected to rise modestly across eight major pharmaceutical markets over the next decade, reaching 7.46 million by 2035, according to UK data and analytics company GlobalData (LSE: DATA).

GlobalData’s latest Hepatitis C Virus: Epidemiology Forecast to 2035 report predicts diagnosed prevalent cases will increase from 7.19 million in 2025 to 7.46 million in 2035, an annual growth rate of 0.4%.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Company Spotlight



More Features in Pharmaceutical